PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21233403-10	2011	When combined with sunitinib, sorafenib, bevacizumab, irinotecan, or docetaxel, Ang2 CovX-Bodies produced even greater efficacy (~80% TGI, P < 0.01).	Sunitinib	19-28	angiopoietin 2	Homo sapiens	80-84	
18316579-6	2008	Furthermore, both sunitinib-treated groups maintained the molecular balance between angiopoietins Ang-1 and Ang-2, suggesting a critical role of angiopoietins in vascular normalization.	Sunitinib	18-27	angiopoietin 2	Homo sapiens	108-113	
25100134-9	2014	CONCLUSIONS: Serum Ang-2 and MMP-2 and tumor HIF-1alpha were identified as relevant baseline biomarkers of sunitinib activity in advanced RCC, warranting further research into their prognostic versus predictive value.	Sunitinib	107-116	angiopoietin 2	Homo sapiens	19-24	
27100185-0	2016	Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.	Sunitinib	77-86	angiopoietin 2	Homo sapiens	15-29	
27100185-5	2016	Ang2 protein expression was restrained to RCC tumour vessels, and correlated with tumour vascularization and response to sunitinib.	Sunitinib	121-130	angiopoietin 2	Homo sapiens	0-4	
27100185-8	2016	In summary, in this study to investigate endothelial Ang2 in mRCC patients treated with first-line sunitinib, high cancer Ang2 expression was associated with the CBR, but not PFS or OS, whereas low Ki-67 expression was significantly associated with long PFS and OS.	Sunitinib	99-108	angiopoietin 2	Homo sapiens	53-57	
21953673-9	2012	During sunitinib treatment, circulating Ang-2 and sTie-2 significantly decreased (p < 0.001 for both), plasma levels of sVCAM-1 and VEGF significantly increased (p = 0.022 and p < 0.001), whereas those of sICAM-1 and vWF remained stable.	Sunitinib	7-16	angiopoietin 2	Homo sapiens	40-45	
24704536-6	2014	Plasma Ang2 decreased with sunitinib treatment and increased at time of disease progression.	Sunitinib	27-36	angiopoietin 2	Homo sapiens	7-11	
24704536-7	2014	In the RCC mouse, dual Ang1/2 and Ang2 inhibition improved the activity of sunitinib.	Sunitinib	75-84	angiopoietin 2	Homo sapiens	34-38	
24704536-9	2014	Thus, Ang2 inhibition, independent of Ang1 inhibition, improves the activity of sunitinib and plasma Ang2 increases in the setting of progression on sunitinib possibly contributing to resistance.	Sunitinib	80-89	angiopoietin 2	Homo sapiens	6-10	
24704536-9	2014	Thus, Ang2 inhibition, independent of Ang1 inhibition, improves the activity of sunitinib and plasma Ang2 increases in the setting of progression on sunitinib possibly contributing to resistance.	Sunitinib	149-158	angiopoietin 2	Homo sapiens	6-10	
24704536-9	2014	Thus, Ang2 inhibition, independent of Ang1 inhibition, improves the activity of sunitinib and plasma Ang2 increases in the setting of progression on sunitinib possibly contributing to resistance.	Sunitinib	149-158	angiopoietin 2	Homo sapiens	101-105	
23730410-11	2013	CONCLUSION: Ang-2 could potentially identify a patient population that might have a better PFS when under anti-angiogenic treatment, like the tyrosine kinase inhibitor sunitinib.	Sunitinib	168-177	angiopoietin 2	Homo sapiens	12-17	
21953673-13	2012	In conclusion, sunitinib-induced changes in Ang-2, sTie-2, sVCAM-1 and VEGF are related to the administration schedule, while reduction in Ang-2 is also associated with decrease in tumor burden.	Sunitinib	15-24	angiopoietin 2	Homo sapiens	44-49	
21953673-13	2012	In conclusion, sunitinib-induced changes in Ang-2, sTie-2, sVCAM-1 and VEGF are related to the administration schedule, while reduction in Ang-2 is also associated with decrease in tumor burden.	Sunitinib	15-24	angiopoietin 2	Homo sapiens	139-144